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Scenario analysis of the future of clinical pharmacy
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Introduction
Since the foundation of the European Society of 
Clinical Pharmacy (ESCP) in 1979, there has been a 
continuous debate about the objectives, roles and 
added value to patient care of clinical pharmacists. In 
1983, ESCP compiled an education document with 
requirements and standards for the expertise and 
skills of clinical pharmacists [1], In the same year, the 
Federation Internationale Pharmaceutique (FIP) pub­
lished the proceedings of the symposium on the 
'Roles and Responsibilities of the Pharmacists in 
Primary Health Care' in Copenhagen, from which 
ensued challenging conclusions on the clinical roles 
of community pharmacists [2]. Since then, the World 
Health Organisation, the Nuffield Foundation and 
many other institutions have recognised and cham­
pioned pharmacists as essential health care providers 
[3 4].
In 1992, ESCP reinforced this position in its publi­
cation The Future of Clinical Pharmacy in Europe' [5]. 
These published statements reflect the rapidly chang­
ing role of pharmacists in the health care system. This 
change is almost universal among different countries 
and is related to developments in medical technolo­
gy, health economics, informatics, socioeconomics, 
and professional relations [6 7]. The autonomy of 
almost all clinical practitioners, including medical 
practitioners and clinical pharmacists, in the choice of 
diagnostic and therapeutic approaches has been 
eroded in various ways in recent decades. The pres­
sures of changes in legislation and regulation, the 
increasing role of insurers and other third parties have 
combined with the development of protocols and 
guidelines and the growing influence of the 
patient/consumer [8 9],
The concept of pharmaceutical care has developed 
from the practice of clinical pharmacy [10] and while 
it has been influential in contributing new approaches 
to education, practice and research, the transitions to 
new systems of health care delivery are difficult to 
anticipate. Even with well defined professional tar­
gets, it remains uncertain what the future of clinical 
pharmacy will bring us [5]. In today's circumstances 
forecasts and target-setting scenarios might have only 
limited value in deciding future policy. A range of 
plausible scenarios are perhaps required to help us 
better prepare for the 'new world' ahead [11 ].
At the annual congresses of ESCP in Prague 1995 
(24th) and Lisbon 1996 (25th), we moderated a 
number of scenario analysis workshops with respect 
to the future of clinical pharmacy. In Lisbon 1996, 
there was special focus on the future role of the clini­
cal pharmacist in optimizing pharmacotherapy. 
Delegates have been participating actively in this pro­
cess and contributed a great deal in identifying and 
evaluating the driving forces behind the develop­
ments in clinical pharmacy and in constructing alter­
native scenarios. In this paper we report from these 
scenario planning workshops and will present the rel­
evant results in the context of policy making by the 
profession.
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Abstract
The role of clinical pharmacy in the health care system is 
changing rapidly This change is almost universal among 
different countries and is related to developments in medical 
technology, health economics, informatics, socio-economic 
status, and professional relations.Transitions to new systems 
of clinical pharmacy are difficult to anticipate. Even with well 
defined targets, it remains uncertain what the future of 
clinical pharmacy will bring us. The construction of plausible 
scenarios may help us better in preparing for the 'new world' 
ahead.
At the annual congresses of ESCP in Prague 1995 (24th) and 
Lisbon 1996 (25th), a number of scenario analysis workshops 
with respect to the future of clinical pharmacy were 
organized. This paper gives a report of the results of these 
scenario sessions and reflects on the implications for future 
policy making. After we identified the driving forces behind 
the future of clinical pharmacy various sets of assumptions 
were made and from them scenarios were constructed which 
are plausible: they 'could' happen. This analysis provided a 
logical framework in which we ultimately depicted three 
alternating stories of the future of clinical pharmacy, named 
'CLERK', 'CONTROLLER' and 'CARE MANAGER', These 
scenarios are intended to help clinical pharmasists to break 
free of familiar mental maps and to stimulate creative 
thinking on the future.
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Methods
Scenario analysis was introduced to participants as a 
form of futures research which since the 1980s has 
emerged as a technique which aims to centre not on 
single forecasts or targets but on plausible scenarios - 
futures which 'could' come about as a result of 
present or emergent trends. This approach has grown 
in popularity as modern society has grown more 
complex. Thus, such scenarios are 'stories of the 
future' which are both conceivable and consistent in 
the light of our knowledge of the present and past
[11]. Preparing for plausible futures helps us generate 
the mental awareness, knowledge and interpretation 
needed to deal with the 'real' future. The aim of sce­
narios is to help policy makers to take a long view 
and, by doing so, to step outside current limited con­
cepts and to make the readjustments in 'mindset' to 
be prepared adequately for the future. A systemic 
step-approach is an important prerequisite in devel­
oping scenarios; we adopted this approach from the 
work of Schwartz on scenario analysis [11] and have 
successfully applied it in the scenario analysis on the 
future of medicines [12].
Small groups of delegates in syndicate sessions 
were facilitated through the process of the identifica­
tion of major trends and forces (the 'driving forces') 
behind today's world of clinical pharmacy. After we 
identified the predetermined elements from this list of 
driving forces, we were left with a number of uncer­
tainties. A critical uncertainty, is an uncertainty that is 
key to the future of clinical pharmacy. These uncer­
tainties play an important role in selecting the most 
critical dimensions and these may be capable of being 
better understood by simplifying and resolving them 
into one or two axes, called 'scenario drivers'. On the 
basis of various sets of assumptions derived from that 
analysis, scenarios were constructed which are plau­
sible - they 'could' happen. Finally, we evaluated the 
features of these scenarios in different groups within 
ESCP in order to adjust and further refine the initial 
(crude) analyses. During the Lisbon sessions, the sce­
narios were also contrasted against the question of 
what future roles clinical pharmacists could have in 
optimizing pharmacotherapy.
Results
The scanning of possible clues for 'driving forces' 
resulted in a long and extensive listing of a wide 
range of candidates, representing developments, 
forces and observations in clinical pharmacy and 
health care in general. After regrouping these, a total 
of six 'driving forces' were identified.
1 Increased need to demonstrate added value of 
pharmaceutical services
There is continuous pressure on the profession of clin­
ical pharmacy to make its role visible and to demon­
strate its added value to benefit both patient outcome 
and economic criteria. Justification of pharmacy ser­
vices is more and more required by payers and hospi­
tal managers to counter the rationing of resources. To 
acquire a share of the health care budget has become 
a matter of demonstrating 'evidence-based' practice, 
not only for pharmacists but for many health care 
professionals.
2 Patient focus
Patients and other health care consumers, especially 
those concerned with particular types of disease 
(chronic diseases, AIDS), bring political pressure to 
bear with a view to increasingly maximizing the avail­
ability of relevant services. Society also continues to 
seek improved protection in terms of provider liability 
and safety of medical technology. Demographics add 
to these developments in terms of increasing the 
need for care of the chronically ill.
3 Changes in the market place and in decision 
making
Patterns of power in health care are shifting as the 
position of health care providers weakens. New 
players, including insurer-based pharmaceutical ben­
efit schemes, managed care organizations, are taking 
over new powerful positions in the health care arena. 
New configurations of health care purchasers and 
health care providers are catalysts of a dramatic 
change in decision-making power, over-riding the 
one-to-one relationship between the health care pro­
vider and the patient.
4 New technology, robotics and the expansion of 
information technology (IT)
The successful synergy of basic sciences with technol­
ogy has accelerated information technology, materi­
als technology and biotechnology, which increases 
the likelihood of future breakthroughs in drug treat­
ment. The management of these new treatments will 
require advanced pharmaceutical expertise and new 
skills. The growth of information technology facili­
tates risk monitoring, the automation of routine pro­
cedures and will provide increased opportunity for 
feedback of data to help the implementation and 
control of therapies and to provide strategic manage­
ment information.
5 Shift to disease orientation
Traditionally, drug compounding, distribution servic­
es and quality assurance were key components of 
pharmacy practice. These product-oriented tasks are 
diminishing, with a shift to more clinical and disease- 
oriented tasks. This driving force is not specific to the 
profession of pharmacy; but reflects a more general 
paradigm shift in patient care, where disease man­
agement is becoming seen holistically, rather than as 
a series of processes of detection, diagnosis, treat­
ment and follow-up.
6 Changes in training and education
Pharmacy education has increasingly become more 
patient orientated, particularly in the past decade, 
preparing new pharmacy professionals for promi­
nence in pharmacotherapy, delivery of clinical servic­
es, computerisation and formulary management. 
However, the innovators within the profession and 
the educational institutions generate role models who 
are influential but not necessarily accepted by all 
pharmacists. Demographically, today two out of three 
pharmacy graduates are females, and these changes 
have a major influence on the emerging role models 
and on professional attitudes.
axis 1: professional autonomy 
axis 2: drug-patient orientation
Figure 1
Three scenarios of the future of clinical pharmacy aiong
two axes,
whether the profession will reconcile itself to its origi­
nal turf, the drug product (axis 2: orientation to drug 
versus patient). These two dimensions provide the 
framework in which we ultimately depicted three 
alternating visions of the future of clinical pharmacy 
namely 'CLERK', 'CONTROLLER' and 'CARE 
MANAGER' (Fig. 1).
Table 1 shows how the major features of the three 
scenarios are listed. The 'CLERK'-scenario is driven by 
a transition back to the original turf of 'traditional' 
pharmacy practice where pharmacists operate as 
drug oriented employees, have low professional stat­
us and have in a limited and dependent role in opti­
mizing pharmacotherapy. In the CONTROLLER-sce- 
nario, pharmacists are the guardians of accountability 
and protocol based practice. They are in charge of 
budget control and have far reaching responsibilities 
to 'control' prescribing behaviour. The CARE MANAG- 
ER-scenario is strongly patient focused with large set 
of independent responsibilities for treatment and care 
strategies. In this scenario, pharmacists are partners 
to physicians and are proactive in setting standards.
Scenario axes
We resolved those uncertainties, sharing some com­
monality into two orthogonal axes. Then we defined 
a matrix (two axes crossing) that allows us to define in 
theoretical terms four distinct, but plausible, quad­
rants of uncertainty. The successful increase in visibil­
ity of the added value of the pharmacist to the drug 
use process, thereby reasserting professional autono­
my, was found to represent one important dimension 
(axis 1: professional autonomy-high versus low). A 
critical uncertainty remains around whether the shift 
to patient orientation in pharmacy can be main­
tained, whether consistency can be established inter­
nationally - or paradoxically given today's forces -
D iscussion
The value of scenario analysis lies in the stimulation of 
thinking and debate on the future. The participants of 
the scenario analysis workshops were prompted to 
think in ways that help them to prepare themselves, 
in terms of their knowledge, skills, activities and atti­
tudes, for what the future holds. It is important to 
break free of old mental habits if we are to remap our 
professional course by approaching the future with an 
open mind. The results of the different sessions pro­
vided three different scenarios, all of which represent­
ed plausible futures. Observation of the international 
scene of pharmacy today provides evidence of the 
features of all three scenarios. For instance, the phar­
macy department at Duke University in the US recent­
Table 1 Three scenarios of the future of clinical pharmacy in key words
Clerk Controller Care manager
Driven by Back to original turf, 
employee, logistics
Custodian,
accountability
In charge of personal 
care, patient first
Professional status Low Moderate High
Model of attitudes Passive Reactive Proactive
Focus and target Logistics Protocol Patient
Relationship to physicians Dependent Watch dog Partner
Impact of female 
pharmacists
High Low High
Optimizing
pharmacotherapy
Limited role, whistle 
blower for the doctor
Budget control, 
disease management
Partnership, dual 
commitment with 
doctors
Opportunity for 
outsourcing services
Limited; clerks need 
inside supervising
Good; external 
accounting model
No, is based on
long-standing
relationship
ly dealt successfully with a re-engineering initiative 
substantiating the value of the pharmacy's services to 
the medical centre and its patients (CARE MANAGER- 
scenario) [1 3]. In this project, the clinical pharmacy 
department actually gained 1 pharmacist FTE in a cli­
mate of reduction of FTEs for other departments and 
a loss of 800 FTEs for the entire medical centre. An 
example showing a different emphasis is the develop­
ment of so-called clinical pharmacy companies [14]. 
These organisations provide services for identifying 
opportunities for drug cost savings in managed care 
plans and for drug use review programs [15]. 
Although such companies employ clinical pharma­
cists, they represent very well the features of the 
'CONTROLLER'-scenario. The pharmacist is not at 
stake but fulfils a cost-containment role.
What can we learn from such scenario planning 
exercises? Many of the health-care changes set in 
motion in the early 1980s are rooted in an interplay of 
factors as the drive for better control and accountabil­
ity, cost-containment and pressures for professionals 
to demonstrate the added value of their services. The 
debate on limits to care brings in various social and 
ethical issues as well. The distribution of scarce 
resources, the need for efficiency, and the far-reach­
ing implications of health care technology are promi­
nent today.
The scenarios presented here are intended to help 
clinical pharmacists in their mission to serve patients 
and doctors in a changing world. None of the three 
will probably represent the 'rear future, but anticipat­
ing them in a creative and strategic way will provide a 
framework for clinical pharmacists to be prepared and 
to adjust their mental maps. Moreover, the scenarios 
can be used in a proactive way in stimulating a drive 
to create new practice standards in the profession and 
to underpin new leadership initiatives in a rapidly 
changing society [16]. Here, we should be aware of 
the risk in losing the followers of change. Birenbaum 
has pointed out the paradox that the profession 
needs innovative leaders to make progress but that a 
great majority of the profession will miss the link with 
these leaders when timing and pace of progress are 
not appreciated by this majority [17]. For ESCP, we 
believe there lies an important responsibility to build
w
bridges between the leaders in innovative practice 
concepts and the rest of the profession. We all lose, 
when society judges the role of clinical pharmacists 
by judging the value of its weakest link in the chain.
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